Press release
Metastatic Prostate Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals
Explore our latest breakthroughs in metastatic prostate cancer research. Learn more about our innovative pipeline today! @ Metastatic Prostate Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Prostate Cancer Pipeline Report
* June 2024:- Janssen Biotech Inc.-The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected.
* June 2024:- Merck Sharp & Dohme LLC- A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
* June 2024:- Aragon Pharmaceuticals Inc.- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer. The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
* June 2024:- Arcus Biosciences Inc.- A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer. This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
* June 2024:- Epizyme Inc.- A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer. This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with either enzalutamide or abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy profiles.
* DelveInsight's Metastatic Prostate Cancer pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
* The leading Metastatic Prostate Cancer Companies such as Tavanta Therapeutics, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORIC Pharmaceuticals, Telix Pharmaceuticals (Innovations) Pty Limited, Orion Corporation, OncoC4 Inc., Bristol-Myers Squibb/Ono Pharmaceuticals, Janssen Research & Development LLC, Merck Sharp & Dohme LLC, Modra Pharmaceuticals, Minneamrita Therapeutics LLC, AB Science, Cellbion Co., Ltd., Allarity Therapeutics, Janssen Research & Development, LLC, Hansoh BioMedical R&D Company, Jiangsu HengRui Medicine Co., Ltd., Hinova Pharmaceuticals Inc., ValiRx Plc, Epizyme Inc., Astrazeneca, and others.
* Promising Metastatic Prostate Cancer Therapies such as Androgen Deprivation Therapy, Docetaxel, Nivolumab, Tazemetostat, Abiraterone/prednisone, Enzalutamide, and others.
Stay informed about the cutting-edge advancements in metastatic prostate cancer treatments. Download for updates and be a part of the revolution in cancer care @ Metastatic Prostate Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Prostate Cancer Emerging Drugs Profile
* TAVT-45: Tavanta Therapeutics
TAVT-45 is a novel oral suspension of abiraterone acetate. It was designed as an alternative abiraterone acetate formulation with clear benefits over branded Zytiga tablets. TAVT-45 granules are rapidly reconstituted in water or juice and easily consumed, which could aid the ~20-30% of patients who have dysphagia or difficulty swallowing.5,6 In clinical studies with TAVT-45, variability in abiraterone exposure was reduced compared to Zytiga, and bioavailability was enhanced in subjects in a fasted state. The improved absorption profile allows for a reduction in the total daily dose of TAVT-45 compared to Zytiga and may potentially improve exposure to therapeutic abiraterone concentrations over 24 h. The large food effect of Zytiga is also avoided, and it is anticipated TAVT-45 to be dosed without regard to meals.
* Onvansertib: Cardiff Oncology
Onvansertib is a first-in-class, third-generation, oral and highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK1) enzyme, which is over-expressed in multiple cancers including leukemias, lymphomas and solid tumors. Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3), is orally administered and has a 24-hour half-life with only mild-to-moderate side effects reported. Currently, the drug is in Phase II stage of its development for the treatment of prostate cancer.
* ONCT-534: Oncternal Therapeutics
ONCT-534, Dual-Action Androgen Receptor Inhibitor (DAARI) candidate, is a novel investigational, potentially first-in-class, orally bioavailable, dual-action androgen receptor (AR) inhibitor, designed to treat patients with metastatic castration-resistant prostate cancer and other androgen receptor-driven diseases. Currently, the drug is in Phase I/II stage of its development for the treatment of prostate cancer.
* VIO-01: Valerio Therapeutics
VIO-01 is designed to abrogate several DNA repair pathways and trigger a robust immune response by activating the innate immune response through the STING pathway. The STING pathway plays a critical role in detecting DNA abnormalities and activating the immune system to target and destroy cancer cells. VIO-01 is currently undergoing proof-of-concept IND-enabling preclinical studies, alone and in combination with cancer immunotherapies. Currently, the drug is in Phase I/II stage of its development for the treatment of prostate cancer.
* ORIC-944: ORIC Pharmaceuticals
ORIC-944 is a potent, orally bioavailable, highly selective allosteric small molecule inhibitor of PRC2, the complex which tri-methylates histone H3 lysine 27 (H3K27me3) via targeting the embryonic ectoderm development (EED) subunit. Currently, the drug is in Phase I stage of its development for the treatment of prostate cancer.
Learn more about Metastatic Prostate Cancer drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Metastatic Prostate Cancer Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Metastatic Prostate Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in metastatic prostate cancer treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Metastatic Prostate Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Prostate Cancer Pipeline Report
* Coverage- Global
* Metastatic Prostate Cancer Companies- Tavanta Therapeutics, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORIC Pharmaceuticals, Telix Pharmaceuticals (Innovations) Pty Limited, Orion Corporation, OncoC4 Inc., Bristol-Myers Squibb/Ono Pharmaceuticals, Janssen Research & Development LLC, Merck Sharp & Dohme LLC, Modra Pharmaceuticals, Minneamrita Therapeutics LLC, AB Science, Cellbion Co., Ltd., Allarity Therapeutics, Janssen Research & Development, LLC, Hansoh BioMedical R&D Company, Jiangsu HengRui Medicine Co., Ltd., Hinova Pharmaceuticals Inc., ValiRx Plc, Epizyme Inc., Astrazeneca , and others.
* Metastatic Prostate Cancer Therapies- Androgen Deprivation Therapy, Docetaxel, Nivolumab, Tazemetostat, Abiraterone/prednisone, Enzalutamide , and others.
* Metastatic Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Prostate Cancer pipeline on our website @ Metastatic Prostate Cancer Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic Prostate Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Prostate Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* TAVT-45: Tavanta Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Onvansertib: Cardiff Oncology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* VIO-01: Valerio Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Prostate Cancer Key Companies
* Metastatic Prostate Cancer Key Products
* Metastatic Prostate Cancer- Unmet Needs
* Metastatic Prostate Cancer- Market Drivers and Barriers
* Metastatic Prostate Cancer- Future Perspectives and Conclusion
* Metastatic Prostate Cancer Analyst Views
* Metastatic Prostate Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-prostate-cancer-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Prostate Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals here
News-ID: 3540057 • Views: …
More Releases from ABNewswire
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
Caliente Brands Brings Bold Heat to Premium Beef Jerky Market with Authentic Spi …
Caliente Brands, LLC launches CalienteJerky.com, offering hickory-smoked beef jerky crafted exclusively from 100% USDA Approved Beef with uniquely spicy flavor profiles. The veteran-owned company targets consumers seeking bold, adventurous snack options with flavors ranging from Spicy Peppered to innovative Spicy Birria, delivering what the brand promises: where smoky and spicy meet delicious.
Caliente Brands, LLC has officially entered the premium beef jerky market with a clear mission: to deliver authentic spicy…
Patio Elegance Expands Luxury Collection to Create the Ultimate High-End Outdoor …
Patio Elegance announces an expanded portfolio of premium outdoor living solutions, ranging from professional-grade kitchen islands and grills to advanced wellness installations like cold plunges, jacuzzis, and handcrafted saunas. This comprehensive collection allows homeowners to design fully integrated, resort-style environments focused on culinary excellence, restorative wellness, and sophisticated comfort.
Patio Elegance is transforming how affluent homeowners approach outdoor living by offering a complete suite of luxury products that turn ordinary backyards…
DallasFortWorthInsurance.com Launches as the Premier Online Destination for DFW …
DallasFortWorthInsurance.com, a new venture from the trusted Baxter Insurance Agency, Inc., is now live, offering a comprehensive platform for Dallas-Fort Worth residents to easily compare and secure the best rates on auto, home, and life insurance.
DALLAS-FORT WORTH, TX - Jan 10, 2026 - Baxter Insurance Agency, Inc., a cornerstone of the Texas insurance community for over four decades, is proud to announce the launch of its latest website, DallasFortWorthInsurance.com. This…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
